Consistently, we found more early-stage prostate cancer in PSA-screened patients, with a significantly higher percentage in T1-2, N0 and Gleason≤6 subgroups, compared with patients who had had PSA screening with later diagnosis or a clinical diagnosis. This evidence concerns the gene KLK3 and Familial prostate cancer.